Early Parkinson’s disease patients on rasagiline present with better odor discrimination

Haehner, Antje; Habersack, Angela; Wienecke, Miriam; Storch, Alexander; Reichmann, Heinz; Hummel, Thomas

doi:10.1007/s00702-015-1433-1

Cited by 17 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, cholinergic denervation of the limbic archicortex (assessed through [(11)C]methyl-4-piperidinyl propionate acetylcholinesterase brain positron emission tomography) was found to be a more robust determinant of hyposmia than nigrostriatal dopaminergic denervation in patients with moderately severe PD without dementia (Bohnen et al, 2010). These data are in line with the observation that hyposmia does not improve with levodopa (Tarakad and Jankovic, 2017), while some evidences suggest that rasagiline is associated with significantly better odor discrimination abilities in early-PD patients (Haehner et al, 2015).…”

Section: Smell and Pdsupporting

confidence: 72%

“…As a non-dopaminergic PD manifestation, there are no effective pharmacological treatments for smell impairment, although some data point to a small benefit of rasagiline on smell impairment in early PD (Haehner et al, 2015). Among nonpharmacological treatments, olfactory training has been proven capable to improve smell sensitivity in a small cohort of PD patients (Haehner et al, 2013).…”

Section: Smell and Pdmentioning

confidence: 99%

See 1 more Smart Citation

“Smelling and Tasting” Parkinson's Disease: Using Senses to Improve the Knowledge of the Disease

Oppo

Melis

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

Among non-motor manifestations of Parkinson's Disease (PD), peripheral, sensory symptoms are particularly relevant. Smell dysfunction starts very early and frequently precedes the PD motor symptoms by years (being often a cue to the diagnosis). Moreover, olfactory system could be, together with gut, one of those peripheral sites where PD pathology first develops. Unlike smell loss, the relationship between PD and taste impairment is far less established. It can start early in the course of the disease but more frequently appears in advanced stages, in parallel with the advent of MCI, likely reflecting cortical involvement. Among PD patients has been demonstrated an increase in the frequency of the non-tasters for PROP (prototypical gustatory stimulus, 6-n-propylthiouracil), a genetically determined bitter taste which is mediated by TAS2RS38 receptor, and a significant increase of the recessive non-testing variant of this receptor. TAS2R38 receptors are expressed also in other tissues, such as in the epithelia of the gut and nasal cavities, where they can influence epithelial immunity ad its interaction with microbiota. Those pieces of evidence suggest that not only systematic assessment of taste and smell can be of a remarkable help for clinicians in the early diagnosis, but also that understanding the mechanisms of sensory involvement in PD could increase the knowledge of the pathophysiology of the disease.

show abstract

Section: Smell and Pdsupporting

confidence: 72%

Section: Smell and Pdmentioning

confidence: 99%

“Smelling and Tasting” Parkinson's Disease: Using Senses to Improve the Knowledge of the Disease

Oppo

Melis

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…In two small observational studies we demonstrated that the monoamine oxidase B (MAO-B) inhibitor, rasagiline, improves the SDI test results and improves olfaction in PD patients; this was also the case in rats treated with rasagiline [27,28]. The mechanism by which this is achieved is completely speculative and could even stem from an improvement in cognition.…”

Section: Olfactionmentioning

confidence: 97%

Premotor Diagnosis of Parkinson’s Disease

Reichmann

2017

Neurosci. Bull.

Self Cite

View full text Add to dashboard Cite

Typical Parkinsonian symptoms consist of bradykinesia plus rigidity and/or resting tremor. Some time later postural instability occurs. Pre-motor symptoms such as hyposmia, constipation, REM sleep behavior disorder and depression may antecede these motor symptoms for years. It would be ideal, if we had a biomarker which would allow to predict who with one or two of these pre-motor symptoms will develop the movement disorder Parkinson's disease (PD). Thus, it is interesting to learn that biopsies of the submandibular gland or colon biopsies may be a means to predict PD, if there is a high amout of abnormally folded alpha-synuclein and phosphorylated alpha-synuclein. This would be of relevance if we would have available means to stop the propagation of abnormal alpha-synuclein which is otherwise one of the reasons of this spreading disease PD.

show abstract

“…53,54 However, in a study in more than 200 patients with PD, positive effects of rasagiline treatment on odour discrimination abilities were found in patients with early PD only. 55 Among non-pharmacological treatments, there is convincing evidence that structured training with odours significantly increases olfactory function in PD, 56,57 suggesting that olfactory training might be a promising approach already known from current otorhinolaryngology recommendations. 58…”

Section: Character Of Smell Loss In Parkinson's Diseasementioning

confidence: 99%